Influence of Route of Administration and Liposomal Encapsulation on Blood and Lymph Node Exposure to the Protein VEGF-C156S

VEGF-C156S is a recombinant form of human vascular endothelial growth factor C (VEGF-C), which targets the receptor VEGFR-3 present in the lymphatics. VEGF-C156S has lymphangiogenic properties and may represent a potential therapeutic approach in treating the lymphatic disease lymphedema. In the present study, we tested the hypotheses that (1) subcutaneous (s.c.) injection will provide higher lymphatic exposure than intravenous (i.v.) administration of VEGF-C156S and (2) s.c. injection of liposomal (s.c. Lipo) VEGF-C156S will provide greater lymphatic exposurethan nonliposomal proteins.



Powered by GlobalLink OneLink Software